Zydus Lifesciences Limited vs Laurus Labs Limited
An objective side-by-side of ZYDUSLIFE and LAURUSLABS, both in Pharmaceuticals - Indian - Bulk Drugs & Formln: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-10-16 close
Latest results: ZYDUSLIFE Mar 2026 · LAURUSLABS Jun 2026
At a glance
- Zydus Lifesciences Limited is the larger company by market value, about 1.0 times the size of Laurus Labs Limited.
- On trailing earnings, Zydus Lifesciences Limited trades at the lower P/E (22.1 against 102.1).
- Laurus Labs Limited earns the higher return on equity (20.6% against 18.7%).
- Over three years Zydus Lifesciences Limited has grown profits faster (32% a year against 4%).
- Over the past year the share prices returned +13.0% (ZYDUSLIFE) and +135.0% (LAURUSLABS).
| Metric | Zydus Lifesciences ZYDUSLIFE |
Laurus Labs LAURUSLABS |
|---|---|---|
| Size and price | ||
| Market cap | ₹112,020 Cr | ₹111,310 Cr |
| Share price | ₹1,123.00 | ₹2,060.10 |
| Valuation | ||
| P/E | 22.10 | 102.09 |
| P/B | 4.13 | 21.00 |
| EV/EBITDA | 14.69 | 55.97 |
| PEG | 0.69 | 25.52 |
| Dividend yield | 0.1% | 0.1% |
| Profitability | ||
| ROE | 18.7% | 20.6% |
| ROCE | 21.0% | 18.0% |
| Operating margin | 31.2% | 28.0% |
| Sales (TTM) | ₹27,148 Cr | ₹7,270 Cr |
| Net profit (TTM) | ₹5,070 Cr | ₹1,090 Cr |
| Growth | ||
| Latest quarter sales YoY | +16.2% | +29.1% |
| Latest quarter profit YoY | +14.5% | +123.9% |
| Sales CAGR 3Y | +16.0% | +4.0% |
| Profit CAGR 3Y | +32.0% | +4.0% |
| Sales CAGR 5Y | +12.0% | +7.0% |
| Profit CAGR 5Y | +19.0% | -2.0% |
| Financial strength | ||
| Debt/Equity | 0.46 | 0.48 |
| Interest cover | 16.11 | 7.62 |
| Ownership | ||
| Promoter holding | 75.0% | 27.5% |
| Promoter change (4 qtrs) | +0.01 pp | -0.13 pp |
| Price performance | ||
| Return 1M | +1.40% | +8.11% |
| Return 3M | -1.81% | +34.66% |
| Return 1Y | +13.04% | +134.97% |
| Return YTD | +22.82% | +85.93% |
| Technical condition | ||
| Technical score | 46 | 87 |
| RS rating (1-99) | 73.00 | 95.00 |
| % vs 200-DMA | +9.88% | +46.73% |
| RSI (14) | 44.73 | 60.45 |
| % from 52-week high | -8.85% | -1.24% |
